Rosetta Genomics Receives Patent For Treatment Of Prostate Cancer - Quick Facts

(RTTNews) - Rosetta Genomics Ltd. (ROSG) announced receipt of a Notice of Allowance from the USPTO for U.S. Patent Application, titled "Compositions and Methods for the Prognosis and Treatment of Prostate Cancer." The patent claims the treatment of prostate cancer through the administration of anti-hsa-miR-210 or a sequence having 80% identity thereto, as well as a method for inhibiting the growth or viability of prostate cancer cells using anti-hsa-miR-210 or a sequence having 80% identity thereto.

"When issued, this new U.S. patent will fortify Rosetta Genomics' leadership in microRNA technology and expand our footprint in urological cancers. This patent is important as this biomarker, over-expressed in primary prostate tumors, could be used as a therapeutic target for prostate cancer. We look forward to monetizing this new intellectual property," said Kenneth Berlin, CEO of Rosetta.